10:38 AM EST, 01/13/2025 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) was up, but off day highs at last look on Monday after announcing a shortlist of AI-generated molecules targeting ATR (Ataxia Telangiectasia and Rad3-related protein) with specific designs for central nervous system (CNS) penetration.

This milestone is the first significant deliverable in Rakovina's partnership with Variational AI, which uses their state-of-the-art Enki platform to fast-track the discovery of inhibitors for specific DNA damage response (DDR) kinase targets. According to a statement, ATR is an important drug target due its critical involvement in the DNA damage response (DDR). Its inhibition can lead to selective cancer cell death and improved therapeutic outcomes when combined with other treatments.

Rakovina is broadening its research scope with Variational AI to target additional DDR kinase pathways, with the goal of building a pipeline of next-generation small-molecule therapies.

Rakovina was last seen up $0.005 at $0.18 -- having been up $0.03, to $0.20, on the TSX Venture Exchange earlier.

Price: 0.18, Change: +0.01, Percent Change: +2.86